This trial is testing whether a special type of ultrasound called contrast enhanced ultrasound (CEUS) can show if patients with aggressive breast cancer are responding to treatment faster than traditional scans. The target group is patients with triple negative breast cancer who are receiving a combination of immune therapies. CEUS uses a special dye to make the images clearer, helping doctors see changes in the tumor more quickly.